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Abstract
Intervertebral disc (IVD) degeneration is a major cause of 
pain and disability; yet therapeutic options are limited and 
treatment often remains unsatisfactory. In recent years, 
research activities have intensified in tissue engineering 
and regenerative medicine, and pre-clinical studies have 
demonstrated encourageing results. Nonetheless, the 
translation of new biological therapies into clinical practice 
faces substantial barriers. During the symposium “Where 
Science meets Clinics”, sponsored by the AO Foundation 
and held in Davos, Switzerland, from September 5-7, 
2013, hurdles for translation were outlined, and ways 
to overcome them were discussed. With respect to cell 
therapy for IVD repair, it is obvious that regenerative 
treatment is indicated at early stages of disc degeneration, 
before structural changes have occurred. It is envisaged 
that in the near future, screening techniques and non-
invasive imageing methods will be available to detect early 
degenerative changes. The promises of cell therapy include 
a sustained effect on matrix synthesis, inflammation control, 
and prevention of angio- and neuro-genesis. Discogenic 
pain, originating from “black discs” or annular injury, 
prevention of adjacent segment disease, and prevention of 
post-discectomy syndrome were identified as prospective 
indications for cell therapy. Before such therapy can safely 
and effectively be introduced into clinics, the identification 
of the patient population and proper standardisation of 
diagnostic parameters and outcome measurements are 
indispensable. Furthermore, open questions regarding the 
optimal cell type and delivery method need to be resolved in 
order to overcome the safety concerns implied with certain 
procedures. Finally, appropriate large animal models and 
well-designed clinical studies will be required, particularly 
addressing safety aspects.
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safety.
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Introduction
Intervertebral disc (IVD) degeneration is a major cause 
for neck and low back pain and as such a significant 
public health problem. According to the Global Burden 
of Disease Study, published in The Lancet in December 
2012, low back pain is the leading cause of disability, with 
current estimates of 632 million people affected worldwide 
(Vos et al., 2012). In many cases neither conservative 
nor surgical treatment can provide satisfactory outcome 
for patients and clinicians. Hence there is a critical need 
for new therapies to attenuate disc degeneration and 
restore disc function. Research in the field of regenerative 
medicine and tissue engineering has intensified over 
the last decade, advocating attractive biomaterial, 
cellular and molecular solutions for IVD regeneration. 
Nonetheless, the translation of such new applications 
into clinical practice remains a major roadblock, and 
only few biological treatments have advanced to clinical 
studies. There are still serious hurdles to overcome before 
biological therapies for IVD repair can be introduced to the 
clinic. The aim of the symposium “Where Science meets 
Clinics”, which was sponsored by the AO Foundation 
and held in Davos, Switzerland on September 5-7, 2013, 
was to address these barriers and to discuss strategies to 
overcome them. A diverse group of scientists, clinicians, 
health care industry and regulatory agency representatives 
was invited to present their views of current state of the 
art, major challenges and visions for advancement. This 
position paper focusses on the possibilities and difficulties 
of cell therapies for IVD regeneration. We first outline 
the present state of knowledge and then summarise the 
discussion among scientists and clinicians.
Cell Therapy in Intervertebral Disc Degeneration: 
Current State
In basic or pre-clinical research, one of three biological 
approaches is typically used to address the degenerative 
process: stimulating anabolic processes; modulating 
catabolic processes; and providing new cells. The latter 
approach appears very attractive, given that one important 
feature of IVD degeneration is a decrease in viable and 
functional cell numbers, and a substantial proportion of 
the existing cells are in a senescent state. IVD cells can 
broadly be separated in nucleus pulposus (NP) cells, which 
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are notochordal in the young and resemble chondrocytes 
in adults, and annulus fibrosus (AF) cells, which have 
fibroblast characteristics. The microenvironment, including 
mechanical and osmotic stresses and oxygen tension, has a 
significant effect on the cells, while IVD cells are generally 
characterised by low proliferative capacity.
 Due to the limitations of differentiated IVD cells, 
different stem cell populations have been investigated 
for IVD regeneration. Evidence for the presence of 
endogenous stem/progenitor cells in the IVD has recently 
been accumulating; hence, mobilisation and activation of 
these cell pools appears an attractive strategy for enhancing 
self-repair (Sakai et al., 2012). To date, only in vitro data 
exist on the activation of endogenous stem/progenitor cells, 
and the amount of stem cells might be insufficient at the 
age when disc degeneration becomes a clinical problem. 
Mobilising stem cells from the surrounding tissues may 
be limited by the lack of blood supply. While results from 
organ culture studies have demonstrated the possibility of 
cell homing into degenerative discs (Illien-Junger et al., 
2012), feasible applications of this promising finding in a 
clinical situation still need to be identified.
 Alternatively, stem cells can be directly transplanted 
into the damaged disc. Numerous in vivo studies have been 
performed on the transplantation of mesenchymal stem 
cells (MSCs) in disc degeneration models. Bone marrow 
derived MSCs have been injected into rabbit (Sakai et al., 
2003; Sakai et al., 2005; Sakai et al., 2006), rat (Crevensten 
et al., 2004), canine (Hiyama et al., 2008) and goat (Zhang 
et al., 2011) IVD, and largely demonstrated regenerative 
potential. Furthermore, xenogenic transplantation of 
human MSCs into porcine models (Henriksson et al., 
2009) and injection of adipose tissue derived stem cells 
(Ganey et al., 2009) have also been reported. Promising 
outcomes have moreover been achieved with human disc 
cell or mesenchymal stem cell transplantations (Hohaus et 
al., 2008; Yoshikawa et al., 2010; Orozco et al., 2011) and 
with the delivery of cartilage cells (Acosta et al., 2011). 
Often the cells are delivered with a biomaterial carrier 
based on hydrogels such as hyaluronan or fibrin (Grad 
et al., 2010). Overall the results of these in vivo studies 
have demonstrated that MSCs are able to survive and 
proliferate after implantation into the disc and that they 
acquire phenotypic characteristics of IVD cells. In fact, 
co-culture of MSCs and IVD cells has widely been shown 
to induce an IVD-like phenotype in MSCs and stimulate 
new matrix production by the disc cells. Furthermore, there 
is substantial evidence that MSCs are able to suppress 
inflammatory reactions in the tissue. In spite of these 
promising results, there are serious concerns associated 
with MSC transplantation, including poor cell survival, 
cell leakage through injection site (Vadala et al., 2012), 
unintended differentiation towards osteogenesis, and the 
potential of tumourigenesis.
 When considering cell therapy for IVD regeneration, 
its potential and limitations need to be identified. The 
underlying causes, such as the genetic predisposition, 
ageing, mechanics, smoking or obesity, cannot be addressed 
by cell therapy, and there are no in vivo data to suggest 
we can prevent disc degeneration in the long term. While 
much of the commonly observed disc degeneration may be 
a normal part of ageing, identification of pathological and 
painful conditions remains an active area of investigation, 
and it may be possible to slow or prevent such pathological 
disc degeneration. There are strong data suggesting that we 
can influence early degenerative changes. It is also evident 
that disc degeneration can lead to secondary degenerative 
spinal diseases, such as spinal canal stenosis, degenerative 
spondylolisthesis, facet joint osteoarthritis etc. It may be 
beneficial to apply cell therapy in patients with progressive 
disc degeneration before these diseases become advanced. 
The questions remain, at what stage of degeneration are 
we beyond biological repair and for how long can we halt 
disease progression?
 To date only few clinical trials have been performed 
using cell therapy for IVD repair or regeneration. In the 
Euro Disc study, culture-expanded autologous disc cells 
were applied to patients with disc herniations. Two-year 
follow up data reported significant pain reduction, disc 
height preservation in the treated level, and maintenance 
of hydration in adjacent levels, which were evident only 
in the treatment group (Meisel et al., 2007). NuQu® is an 
innovative approach to disc repair that uses allogeneic 
juvenile (knee) chondrocytes with proven superior 
regenerative potential. The minimally invasive outpatient 
procedure targets disc-related pain and requires minimal 
patient rehabilitation. Studies in rat and porcine discs 
confirmed significantly superior magnetic resonance 
imageing (MRI) and histological outcomes in discs treated 
with the NuQu® system, in comparison to treatment with 
the fibrin carrier (Acosta et al., 2011). A phase I safety 
trial was subsequently performed with 15 patients with 
single level moderate lumbar disc degeneration (Coric 
et al., 2013). Continued improvement in pain scores as 
well as improved or unchanged MRI results could be 
observed from baseline to 6 and 12 months, warranting 
more extended human trials to assess efficacy. An on-going 
phase II clinical trial will assess the safety and effectiveness 
of NuQu® cartilage cell injection into the lumbar disc as 
compared to placebo in 44 subjects.
 While animal and human data on the regenerative 
potential of injected chondrocytes or disc cells are 
promising, there are still open questions with respect to 
timing of treatment, the optimal cell source, cell pre-
treatment, and cell carrier. According to current knowledge, 
the procedure appears safe; though long-term results are 
still unknown.
Cell Therapy for Disc Repair: Who is the Patient?
The most difficult question is to define the level of disc 
degeneration that is beyond biological repair and where an 
established surgical treatment is better indicated. Although 
it is obvious that regenerative treatment is best indicated 
at early stages of disc degeneration, prior to structural 
changes, these non-symptomatic discs usually are not 
seen by spine surgeons/therapists. Nevertheless, it is very 
likely that in the future, screening techniques focussing 
on genetic predisposition for early incidence of disc 
degeneration become available, and non-invasive imageing 
methods, such as quantitative MRI, are sensitive enough 
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to detect early degenerative changes. Several conditions 
were identified as candidates for cell therapy in disc repair.
Discogenic pain
Discogenic pain may originate from “black” discs or 
annular injured discs presenting HIZ (high intensity zones). 
In these cases, discogenic low back pain is believed to 
arise from acute tears or fissures of the AF and from focal 
defects of the outer AF. These defects result in a repair 
process, where granulation tissue is formed along with 
neovascularisation and concomitant ingrowth of nerve 
fibres (Melrose et al., 2002; Freemont et al., 1997; Aoki 
et al., 2006), and degenerated NP and AF cells produce 
neurotrophins that promote neurovascular growth 
(Purmessur et al., 2008). Although the AF has not fully 
lost its main function to withstand the hydrostatic pressure 
from the NP and to stabilise the segment, discogenic low 
back pain has a high likelihood to develop chronicity 
and often needs medical treatment. These discs are ideal 
candidates for cell-based therapies, as no relevant structural 
changes have occurred yet and restoration of disc height, 
intradiscal pressure and mechanical function is possible 
through regeneration of disc matrix. In addition, discogenic 
pain has an inflammatory component where introduction 
of metabolically active cells may have a beneficial, 
regulatory effect. On the other hand, these patients are 
presently not seen by spine surgeons but are treated by 
non-interventional specialists such as rheumatologists and 
general practitioners.
Prevention of adjacent segment disease (ASD)
ASD may be prevented by prophylactic treatment in the 
course of a surgical intervention for a symptomatic level. 
Frequently, discs adjacent to a segment that is fused for 
various indications show already signs of degeneration 
and are likely to also become symptomatic over time. 
Several attempts to reduce the incidence of ASD, such as 
total disc replacement, interspineous spacers or dynamic 
implants, are in clinical use. As these patients are already 
under treatment by spine surgeons and have a high risk 
for progression of the disease on adjacent levels, they 
represent ideal candidates for an attempt to restore the 
biological and biomechanical function of the adjacent 
disc. A phase I safety trial is on-going by a Japanese 
research group at Tokai University regarding cell therapy to 
prevent IVD degeneration in the adjacent disc. They target 
IVDs in patients in their 20s undergoing fusion surgery 
demonstrating mild to moderate degeneration in the IVD 
adjacent to the fusion level. They culture NP cells obtained 
from the IVD undergoing fusion surgery, and subsequently 
co-culture them with autologous MSCs isolated from the 
bone marrow to re-vitalise the NP cells. After re-vitalising, 
NP cells are injected under fluoroscopic guidance to the 
IVD adjacent to the fusion level. Preliminary results in 10 
patients show that this technique seems to have no major 
issues regarding patient safety.
Prevention of post-discectomy syndrome
Partial discectomy for herniation is a common procedure; 
as disc herniation has a lifetime prevalence of 1-3 % and 
often affects active, working persons of 30-50 years of 
age, the socioeconomic impact due to medical treatment 
and long-term absence from work is enormous (Weinstein 
et al., 2006; Weber, 1994). Discectomy has been shown 
to be an effective treatment for acute disc herniation with 
regard to neurological symptoms, but fails to address the 
altered biomechanical properties of the segment and the 
resulting annular defect. In this situation, the surgeon 
faces the dilemma of how extensive a discectomy should 
be performed: if only the extruding material of the NP 
is resected, a relevant risk of recurrent disc herniation 
is well documented; however, if all or most of the NP 
is resected, there is also a significant chance that lost 
biomechanical function leads to instability or collapse 
of the segment (Moore et al., 1994; Kambin et al., 1995; 
Yorimitsu et al., 2001; Suk et al., 2001; Vucetic et al., 
1997), increased disc degeneration and chronic low back 
pain (Barth et al., 2008). NP replacement or regeneration 
to restore the biomechanical function of the disc will only 
be successful in the presence of a functional AF that is 
able to restore function and withstand the physiological 
loading conditions (Veres et al., 2008; Thompson et 
al., 2000; Fazzalari et al., 2001). Synthetic and natural 
biomaterials capable of restoring functional biomechanics 
of the IVD are under development and offer promise for 
NP replacement, AF repair, and as an AF sealant (Iatridis 
et al., 2013). A successful regeneration of both the annulus 
and the nucleus must meet mechanical and biological 
compatibility requirements and is also strongly dependent 
on a sufficient anchorage of the regenerated tissue to the 
surrounding tissue. Cell-based therapies for annular repair 
may be helpful to overcome these barriers.
Total (biological) disc replacement for advanced disc 
degeneration
Total disc replacement by tissue engineered whole organs 
is of course an ambitious goal. Nevertheless, impressive 
advances have been made in whole disc replacement in 
rodents (Bowles et al., 2011). The patient population is 
large and heterogeneous, and a tissue engineered disc might 
be considered for specific indications in the future. So far 
unresolved barriers include the concomitant degeneration 
of the facet joints, ligaments and muscles.
Cell Therapy for Disc Repair: What are the Benefits?
Although the fate of the cells within the harsh environment 
of the disc with limited nutrient supply and transport of 
metabolites is unknown, there are several arguments for 
using cell-based therapies in attempts to regenerate the 
disc:
a) In degenerated discs, a reduced number of cells 
have been found in affected specimens that cannot be 
explained by limited nutrition and ageing alone.
b) Similarly, a loss of cells and matrix has been 
observed in disc herniations, further limiting the 
healing potential of the ruptured AF.
c) The effect of application of growth factors or other 
pharmaceuticals to regenerate the disc is temporally 
limited and may require several repetitive interventions 
or sustained release formulations, whereas the duration 
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of cell-based therapies depends on the survival and 
activity of the cells. Hence, a single stage application 
can have a long-lasting effect.
d) Cells can fulfil several functions, including 
matrix production, prevention of AF deformation, 
inflammation control, production of growth factors and 
prevention of angio- and neuro-genesis. Eventually, 
cells have the potential to interact with the resident 
cell population, regulate local homeostasis and attract 
additional cells (Illien-Junger et al., 2012).
The Need to Close the Gap towards Clinical 
Application
Selection of patients
Identification of suited patient populations is fundamental 
(see above). MRI is an ideal non-invasive screening method, 
and various protocols are available to quantitatively assess 
disc degeneration at early stages (Watanabe et al., 2007; 
Hoppe et al., 2012; Borthakur et al., 2011). Even though 
information on the nutritional status of the disc can be 
obtained (Rajasekaran et al., 2004; Benneker et al., 2005), 
to date these techniques are not yet applied in daily clinical 
use, mostly because of the lack of clinical consequences. 
Since the additional costs and effort to implement these 
modern sequences is moderate, they will most probably be 
implemented in daily routine once a regenerative treatment 
is available.
Standardisation of diagnostic parameters, outcome 
measurements and models
Until now standardised diagnostic parameters and outcome 
measurements for regeneration and repair are lacking. 
To monitor and compare effectiveness of regeneration 
strategies, such outcome measures need to be established 
on a clinical and investigational level. Efforts should 
be made to identify the best suited diagnostic method 
to quantify degenerative changes; ideally, non-invasive 
imageing methods such as quantitative MRI should be 
preferred that are widely available and can be used for 
both experimental and clinical purposes. Biochemically, 
assessment should focus on parameters that either can 
be reproduced on patients or are validated against the 
imageing techniques to be established. Similar to the 
lack of defined outcome parameters, in vivo and in vitro 
degeneration models need to be standardised to compare 
results of different treatments.
Cell type
Several sources have been investigated in cell therapy 
research. Optimal cell sources for clinical application 
are yet to be defined. While stem cells from bone 
marrow or adipose tissue show encourageing results in 
animal models, their senescence in aged adults is well 
documented. Embryonic allograft cells are appealing 
for their regenerative capacity, but their safe use is of 
concern. Autologous or allogeneic chondrocytes appear 
safe and effective in initial clinical trials (see above). 
Standardisation of procedures and longer term studies are 
needed to obtain reliable evidence about effectiveness of 
the treatment.
Delivery methods
Provocative discography has been shown to have a negative 
effect on discs, accelerating degeneration (Carragee et al., 
2009), and this may arise due to altered mechanics around 
the AF defect or due to cytotoxicity of the delivery agent 
(Kang, 2010; Iatridis and Hecht, 2012). Alternative routes 
to deliver cells and other agents into the disc, keeping the 
AF intact, need to be developed (Vadala et al., 2013; Illien-
Junger et al., 2012). Alternatively, proper repair of the AF 
may be an option (Guterl et al., 2013).
Large animal models and clinical studies
Many cell-based therapies have already shown promise 
based on in vitro or small animal models, and relevant 
pre-clinical screening in large animal models is required 
to accelerate translation. In animal models, degeneration 
is usually induced mechanically (stab injury, excessive 
torsion or compression, or removal of NP material), which 
is poorly comparable to the slow degenerative process in 
human discs. There is a need for establishment of large 
animal models that better mimic the disease process in 
humans.
 Ultimately, in the light of approval from regulatory 
institutions (FDA), clinical studies for regenerative 
strategies need to be well designed with solid methodology. 
In particular, studies need to address the safety aspect of 
these treatments.
Conclusion
Due to the slow progressive nature of disc degeneration 
that involves cell senescence, increased catabolic activity 
and decreased matrix synthesis, cell therapy is an appealing 
approach to regenerate the intervertebral disc. This 
potential has already been demonstrated in pre-clinical 
studies, but there are also equally convincing amounts of 
scientific evidence demonstrating that further knowledge 
is required to overcome the hurdles. The most significant 
of these hurdles were identified in the workshop, hopefully 
providing some guidance for future research, in order to 
successfully translate this approach to the clinic for the 
benefit of patients suffering from this all too common and 
morbid condition.
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hence no Discussion with Reviewers section.
